EMA supports encorafenib plus binimetinib combination
medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended marketing authorization be given for the combination of encorafenib and binimetinib in patients with BRAF V600-mutated unresectable or metastatic melanoma.
The joint therapy has also been approved by the US FDA for this indication.
By Lynda Williams
medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group